<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02089464</url>
  </required_header>
  <id_info>
    <org_study_id>NX92325</org_study_id>
    <nct_id>NCT02089464</nct_id>
  </id_info>
  <brief_title>Niche Trial: Navigated Inhibitory rTMS to Contralesional Hemisphere Trial</brief_title>
  <acronym>NICHE</acronym>
  <official_title>Pivotal Phase III, Prospective, Multicenter, Double Blinded, Randomized, Sham Controlled Trial to Determine the Therapeutic Effects of Navigation Guided 1 Hz rTMS Administered to the Contralesional Hemisphere as Adjuvant to Task Oriented Rehabilitation in Patients With Ischemic or Hemorrhagic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nexstim Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nexstim Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pivotal, prospective, multi-center, randomized, controlled, double-blinded study combining&#xD;
      active Nexstim NBS-guided 1Hz rTMS or sham-rTMS targeting the healthy hemisphere with&#xD;
      standardized task oriented rehabilitation will be conducted in patients with post-stroke&#xD;
      motor impairment. The therapy will be provided for 6 weeks and primary outcome assessed 6&#xD;
      months later.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Upper Extremity Fugl-Meyer Score</measure>
    <time_frame>Baseline - 6 months post-treatment</time_frame>
    <description>Number of Participants with Improvement in Upper Extremity Fugl-Meyer (UEFM) Score at 6 Months Post-treatment equal or exceeding the Minimal Clinically Important Difference (MCID) of 5 points (MCID).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arm-Research Action Test (ARAT)</measure>
    <time_frame>Baseline - 6 months post-treatment</time_frame>
    <description>Scale minimum 0, maximum 57. Greater values indicate better motor function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wolf Motor Function Test</measure>
    <time_frame>Baseline - 6 months post-treatment</time_frame>
    <description>Time in seconds to perform test tasks. Shorter time indicates better motor function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH Stroke Scale (NIHSS)</measure>
    <time_frame>Baseline - 6 months post-treatment</time_frame>
    <description>Scale is a measure of neurological functioning, with higher scores reflecting greater deficit (minimum 0,maximum 42)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chedoke-McMaster Stroke Assessment (CMSA)</measure>
    <time_frame>Baseline - 6 months post-treatment</time_frame>
    <description>Scale minimum 1, maximum 7. Higher values indicate better motor function of hand.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke Impact Scale (SIS)</measure>
    <time_frame>Baseline - 6 months post-treatment</time_frame>
    <description>Score used to detect the consequences of stroke on physical functioning and activities of daily living. The SIS-16 is a 16 item survey that inquires about daily tasks performed over the previous 2 weeks. Scale minimum 16, maximum 80. Higher values indicate better function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Health Questionnaire (PHQ9)</measure>
    <time_frame>Baseline - 6 months post-treatment</time_frame>
    <description>The possible presence and severity of depression will be assessed using the Patient Health Questionnaire (PHQ9). PHQ9 is a scale with a minimum value 0 and maximum of 27. Higher values indicate more depressed mood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessment: EuroQol EQ-5D Scale</measure>
    <time_frame>Baseline - 6 months post-treatment</time_frame>
    <description>The EuroQoL EQ-5D is a visual analog scale scale from 0 (minimum) to 100 (maximum) assessing quality of life. Higher values indicate better quality of life.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To Assess Safety of Study Device Use, All Serious Adverse Events Will be Recorded and Compared Between Groups</measure>
    <time_frame>Baseline - 6 months post-treatment</time_frame>
    <description>Serious Adverse Events were recorded and their occurrence was compared between treatment arms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">199</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>NBS-rTMS + task-oriented rehabilitation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NBS-guided rTMS + task-oriented rehabilitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham rTMS + task-oriented rehabilitation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham rTMS + task-oriented rehabilitation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NBS-guided rTMS</intervention_name>
    <arm_group_label>NBS-rTMS + task-oriented rehabilitation</arm_group_label>
    <other_name>Nexstim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham rTMS</intervention_name>
    <arm_group_label>Sham rTMS + task-oriented rehabilitation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Task oriented rehabilitation</intervention_name>
    <arm_group_label>NBS-rTMS + task-oriented rehabilitation</arm_group_label>
    <arm_group_label>Sham rTMS + task-oriented rehabilitation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
          -  ≥ 18 years of age&#xD;
&#xD;
          -  An ischemic or hemorrhagic stroke suffered 3-12 months prior to the study;&#xD;
&#xD;
          -  no other known brain abnormalities by history;&#xD;
&#xD;
          -  A one-sided stroke resulting in upper extremity paresis&#xD;
&#xD;
          -  A Chedoke-McMaster Stroke Assessment arm stage and hand stage of 3-6 for the affected&#xD;
             limb&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Implanted metallic parts of implanted electronic devices, including pacemakers,&#xD;
             defibrillators, or implant medication pump;&#xD;
&#xD;
          -  Pregnant or trying to become pregnant; Lack of pregnancy established in females of&#xD;
             child-bearing potential by a negative urine pregnancy test at screening.&#xD;
&#xD;
          -  Active alcohol abuse, illicit drug use or drug abuse or significant mental illness&#xD;
&#xD;
          -  Patients suffering from depression as measured by a score of &gt;10 on the Patient Health&#xD;
             Questionnaire (PHQ9). For clarity, patients diagnosed with depression which is&#xD;
             controlled with stable anti-depressive medication and in whom PHQ9 is &lt;10 are eligible&#xD;
             to participate in the trial.&#xD;
&#xD;
          -  History of epilepsy, defined as at least two unprovoked seizures occurring greater&#xD;
             than 24 hours apart or diagnosis of an epilepsy syndrome, OR a seizure within the last&#xD;
             12 months.&#xD;
&#xD;
          -  Any condition that would prevent the subject from giving voluntary informed consent;&#xD;
&#xD;
          -  An implanted brain stimulator;&#xD;
&#xD;
          -  Any metal in head with the exception of dental work or any ferromagnetic metal&#xD;
             elsewhere in the body;&#xD;
&#xD;
          -  Enrolled or plans to enroll in an interventional trial during this study;&#xD;
&#xD;
          -  Scalp wounds or infections;&#xD;
&#xD;
          -  Claustrophobia precluding MRI;&#xD;
&#xD;
          -  A fixed contraction deformity in the affected limb that would prevent normal dexterity&#xD;
             if patient were neurologically intact;&#xD;
&#xD;
          -  Excessive spasticity as indicated by the Modified Ashworth Spasticity (MAS) Scale &gt;2/4&#xD;
             in either elbow flexors, wrist flexors or finger flexors of the affected limb;i&#xD;
&#xD;
          -  previous stroke with residual deficits (TIAs not a reason for exclusion);&#xD;
&#xD;
          -  premorbid (retrospective) modified Rankin Scale (mRS) score ≥2 of any aetiology;&#xD;
&#xD;
          -  a concurrent progressive neurologic disorder, acute coronary syndrome, severe heart&#xD;
             disease (NYHA Classification &gt; 3), or other major medical condition,&#xD;
&#xD;
          -  confirmed or suspected lower-limb fracture preventing mobilization,&#xD;
&#xD;
          -  patients requiring palliative care&#xD;
&#xD;
          -  patients planning to undergo any other occupational therapy during the 6 week active&#xD;
             treatment period of the trial (see section 5.2 for study schedule) than what is&#xD;
             provided in the study&#xD;
&#xD;
          -  A recent injection of botulinium toxin to the affected upper limb in the last 3&#xD;
             months, or the need of an injection of botulinum toxin anytime during the study period&#xD;
             and follow up.&#xD;
&#xD;
          -  A recent injection of phenol to the affected upper limb in the last 6 months, or the&#xD;
             need of an injection of phenol anytime during the study period and follow up.&#xD;
&#xD;
          -  Ataxia as measured by a score &gt; 1 on item 7 (limb ataxia) of the NIH stroke scale.&#xD;
&#xD;
          -  Severe sensory deficits as measured by a score of 2 on item 8 of the NIH stroke scale.&#xD;
&#xD;
          -  Severe aphasia as measured by a score of &gt; 2 on item 9 (best language) of the NIH&#xD;
             stroke scale.&#xD;
&#xD;
          -  Severe neglect as measured by a score of 2 on item 11 (extinction and inattention) of&#xD;
             the NIH stroke scale.&#xD;
&#xD;
          -  Patients unable to comprehend or follow verbal commands&#xD;
&#xD;
          -  Based on PI's or local physician's assessment patient unable to tolerate the trial&#xD;
             procedure due to medical condition&#xD;
&#xD;
          -  A Mini mental status exam (MMSE) &lt;25.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard L Harvey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shirley Ryan AbilityLab</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rancho Los Amigos National Rehabilitation Center</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shepherd Rehabilitation Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rehabilitation Institute of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Indianapolis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaulding Rehabilitation Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Cornell New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burke Medical Research Institute, Weill Cornell Neurology</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TIRR Memorial Hermann Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Harvey RL, Edwards D, Dunning K, Fregni F, Stein J, Laine J, Rogers LM, Vox F, Durand-Sanchez A, Bockbrader M, Goldstein LB, Francisco GE, Kinney CL, Liu CY; NICHE Trial Investigators *. Randomized Sham-Controlled Trial of Navigated Repetitive Transcranial Magnetic Stimulation for Motor Recovery in Stroke. Stroke. 2018 Sep;49(9):2138-2146. doi: 10.1161/STROKEAHA.117.020607.</citation>
    <PMID>30354990</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 14, 2014</study_first_submitted>
  <study_first_submitted_qc>March 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2014</study_first_posted>
  <results_first_submitted>August 4, 2020</results_first_submitted>
  <results_first_submitted_qc>August 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 1, 2020</results_first_posted>
  <disposition_first_submitted>September 13, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>September 19, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 27, 2017</disposition_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NBS-rTMS + Task-oriented Rehabilitation</title>
          <description>NBS-guided rTMS + task-oriented rehabilitation&#xD;
NBS-guided rTMS&#xD;
Task oriented rehabilitation</description>
        </group>
        <group group_id="P2">
          <title>Sham rTMS + Task-oriented Rehabilitation</title>
          <description>Sham rTMS + task-oriented rehabilitation&#xD;
Sham rTMS&#xD;
Task oriented rehabilitation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NBS-rTMS + Task-oriented Rehabilitation</title>
          <description>NBS-guided rTMS + task-oriented rehabilitation&#xD;
NBS-guided rTMS&#xD;
Task oriented rehabilitation</description>
        </group>
        <group group_id="B2">
          <title>Sham rTMS + Task-oriented Rehabilitation</title>
          <description>Sham rTMS + task-oriented rehabilitation&#xD;
Sham rTMS&#xD;
Task oriented rehabilitation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="132"/>
            <count group_id="B2" value="67"/>
            <count group_id="B3" value="199"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="13.3"/>
                    <measurement group_id="B2" value="57.6" spread="12.7"/>
                    <measurement group_id="B3" value="58.7" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Upper Extremity Fugl-Meyer</title>
          <description>Scale minimum 0, maximum 66. Higher values indicate better motor function.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.0" spread="12.2"/>
                    <measurement group_id="B2" value="35.0" spread="12.5"/>
                    <measurement group_id="B3" value="34.3" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Arm Research Action Test</title>
          <description>Scale minimum 0, maximum 57. Greater values indicate better motor function</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.3" spread="16.3"/>
                    <measurement group_id="B2" value="30.0" spread="15.8"/>
                    <measurement group_id="B3" value="28.2" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Wolf Motor Function Test</title>
          <description>Time in seconds to perform test tasks. Shorter time indicates better motor function.</description>
          <units>seconds of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.1" spread="48.4"/>
                    <measurement group_id="B2" value="29.4" spread="46.8"/>
                    <measurement group_id="B3" value="31.2" spread="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chedoke-McMaster Stroke Assessment Hand</title>
          <description>Scale minimum 1, maximum 7. HIgher score indicates better function.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.0" spread="0.9"/>
                    <measurement group_id="B2" value="4.1" spread="1.0"/>
                    <measurement group_id="B3" value="4.0" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chedoke-McMaster Stroke Assessment Arn</title>
          <description>Scale minimum 1, maximum 7. Higher values indicate better motor function.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" spread="0.8"/>
                    <measurement group_id="B2" value="3.6" spread="0.9"/>
                    <measurement group_id="B3" value="3.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NIH Stroke Scale</title>
          <description>Scale is a measure of neurological functioning, with higher scores reflecting greater deficit (minimum 0,maximum 42)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.7" spread="1.6"/>
                    <measurement group_id="B2" value="2.3" spread="1.9"/>
                    <measurement group_id="B3" value="2.6" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stroke Impact Scale</title>
          <description>Score used to detect the consequences of stroke on physical functioning and activities of daily living. The SIS-16 is a 16 item survey that inquires about daily tasks performed over the previous 2 weeks. Scale minimum 16, maximum 80. Higher values indicate better function.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.3" spread="16.9"/>
                    <measurement group_id="B2" value="65.3" spread="16.0"/>
                    <measurement group_id="B3" value="64.7" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient Health Questionnaire - 9 (PHQ9)</title>
          <description>The possible presence and severity of depression will be assessed using the Patient Health Questionnaire (PHQ9). PHQ9 is a scale with a minimum value 0 and maximum of 27. Higher values indicate more depressed mood.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" spread="2.9"/>
                    <measurement group_id="B2" value="3.7" spread="3.2"/>
                    <measurement group_id="B3" value="3.6" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EuroQol ED-5Q scale</title>
          <description>The EuroQoL EQ-5D is a visual analog scale scale from 0 (minimum) to 100 (maximum) assessing quality of life. Higher values indicate better quality of life.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.2" spread="18.4"/>
                    <measurement group_id="B2" value="70.4" spread="17.9"/>
                    <measurement group_id="B3" value="68.8" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Upper Extremity Fugl-Meyer Score</title>
        <description>Number of Participants with Improvement in Upper Extremity Fugl-Meyer (UEFM) Score at 6 Months Post-treatment equal or exceeding the Minimal Clinically Important Difference (MCID) of 5 points (MCID).</description>
        <time_frame>Baseline - 6 months post-treatment</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>NBS-rTMS + Task-oriented Rehabilitation</title>
            <description>NBS-guided rTMS + task-oriented rehabilitation&#xD;
NBS-guided rTMS&#xD;
Task oriented rehabilitation</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS + Task-oriented Rehabilitation</title>
            <description>Sham rTMS + task-oriented rehabilitation&#xD;
Sham rTMS&#xD;
Task oriented rehabilitation</description>
          </group>
        </group_list>
        <measure>
          <title>Upper Extremity Fugl-Meyer Score</title>
          <description>Number of Participants with Improvement in Upper Extremity Fugl-Meyer (UEFM) Score at 6 Months Post-treatment equal or exceeding the Minimal Clinically Important Difference (MCID) of 5 points (MCID).</description>
          <population>Intent to treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arm-Research Action Test (ARAT)</title>
        <description>Scale minimum 0, maximum 57. Greater values indicate better motor function.</description>
        <time_frame>Baseline - 6 months post-treatment</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>NBS-rTMS + Task-oriented Rehabilitation</title>
            <description>NBS-guided rTMS + task-oriented rehabilitation&#xD;
NBS-guided rTMS&#xD;
Task oriented rehabilitation</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS + Task-oriented Rehabilitation</title>
            <description>Sham rTMS + task-oriented rehabilitation&#xD;
Sham rTMS&#xD;
Task oriented rehabilitation</description>
          </group>
        </group_list>
        <measure>
          <title>Arm-Research Action Test (ARAT)</title>
          <description>Scale minimum 0, maximum 57. Greater values indicate better motor function.</description>
          <population>Intent to treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="7.7"/>
                    <measurement group_id="O2" value="5.0" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.80</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wolf Motor Function Test</title>
        <description>Time in seconds to perform test tasks. Shorter time indicates better motor function.</description>
        <time_frame>Baseline - 6 months post-treatment</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>NBS-rTMS + Task-oriented Rehabilitation</title>
            <description>NBS-guided rTMS + task-oriented rehabilitation&#xD;
NBS-guided rTMS&#xD;
Task oriented rehabilitation</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS + Task-oriented Rehabilitation</title>
            <description>Sham rTMS + task-oriented rehabilitation&#xD;
Sham rTMS&#xD;
Task oriented rehabilitation</description>
          </group>
        </group_list>
        <measure>
          <title>Wolf Motor Function Test</title>
          <description>Time in seconds to perform test tasks. Shorter time indicates better motor function.</description>
          <population>Intent to treat</population>
          <units>seconds of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="29.5"/>
                    <measurement group_id="O2" value="-10.6" spread="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NIH Stroke Scale (NIHSS)</title>
        <description>Scale is a measure of neurological functioning, with higher scores reflecting greater deficit (minimum 0,maximum 42)</description>
        <time_frame>Baseline - 6 months post-treatment</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>NBS-rTMS + Task-oriented Rehabilitation</title>
            <description>NBS-guided rTMS + task-oriented rehabilitation&#xD;
NBS-guided rTMS&#xD;
Task oriented rehabilitation</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS + Task-oriented Rehabilitation</title>
            <description>Sham rTMS + task-oriented rehabilitation&#xD;
Sham rTMS&#xD;
Task oriented rehabilitation</description>
          </group>
        </group_list>
        <measure>
          <title>NIH Stroke Scale (NIHSS)</title>
          <description>Scale is a measure of neurological functioning, with higher scores reflecting greater deficit (minimum 0,maximum 42)</description>
          <population>Intent to treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.3"/>
                    <measurement group_id="O2" value="-0.7" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chedoke-McMaster Stroke Assessment (CMSA)</title>
        <description>Scale minimum 1, maximum 7. Higher values indicate better motor function of hand.</description>
        <time_frame>Baseline - 6 months post-treatment</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>NBS-rTMS + Task-oriented Rehabilitation</title>
            <description>NBS-guided rTMS + task-oriented rehabilitation&#xD;
NBS-guided rTMS&#xD;
Task oriented rehabilitation</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS + Task-oriented Rehabilitation</title>
            <description>Sham rTMS + task-oriented rehabilitation&#xD;
Sham rTMS&#xD;
Task oriented rehabilitation</description>
          </group>
        </group_list>
        <measure>
          <title>Chedoke-McMaster Stroke Assessment (CMSA)</title>
          <description>Scale minimum 1, maximum 7. Higher values indicate better motor function of hand.</description>
          <population>Intent to treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.0"/>
                    <measurement group_id="O2" value="0.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroke Impact Scale (SIS)</title>
        <description>Score used to detect the consequences of stroke on physical functioning and activities of daily living. The SIS-16 is a 16 item survey that inquires about daily tasks performed over the previous 2 weeks. Scale minimum 16, maximum 80. Higher values indicate better function</description>
        <time_frame>Baseline - 6 months post-treatment</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>NBS-rTMS + Task-oriented Rehabilitation</title>
            <description>NBS-guided rTMS + task-oriented rehabilitation&#xD;
NBS-guided rTMS&#xD;
Task oriented rehabilitation</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS + Task-oriented Rehabilitation</title>
            <description>Sham rTMS + task-oriented rehabilitation&#xD;
Sham rTMS&#xD;
Task oriented rehabilitation</description>
          </group>
        </group_list>
        <measure>
          <title>Stroke Impact Scale (SIS)</title>
          <description>Score used to detect the consequences of stroke on physical functioning and activities of daily living. The SIS-16 is a 16 item survey that inquires about daily tasks performed over the previous 2 weeks. Scale minimum 16, maximum 80. Higher values indicate better function</description>
          <population>Intent to treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="11.6"/>
                    <measurement group_id="O2" value="8.7" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Health Questionnaire (PHQ9)</title>
        <description>The possible presence and severity of depression will be assessed using the Patient Health Questionnaire (PHQ9). PHQ9 is a scale with a minimum value 0 and maximum of 27. Higher values indicate more depressed mood</description>
        <time_frame>Baseline - 6 months post-treatment</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>NBS-rTMS + Task-oriented Rehabilitation</title>
            <description>NBS-guided rTMS + task-oriented rehabilitation&#xD;
NBS-guided rTMS&#xD;
Task oriented rehabilitation</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS + Task-oriented Rehabilitation</title>
            <description>Sham rTMS + task-oriented rehabilitation&#xD;
Sham rTMS&#xD;
Task oriented rehabilitation</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Health Questionnaire (PHQ9)</title>
          <description>The possible presence and severity of depression will be assessed using the Patient Health Questionnaire (PHQ9). PHQ9 is a scale with a minimum value 0 and maximum of 27. Higher values indicate more depressed mood</description>
          <population>Intent to treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="3.3"/>
                    <measurement group_id="O2" value="0.0" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Assessment: EuroQol EQ-5D Scale</title>
        <description>The EuroQoL EQ-5D is a visual analog scale scale from 0 (minimum) to 100 (maximum) assessing quality of life. Higher values indicate better quality of life.</description>
        <time_frame>Baseline - 6 months post-treatment</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>NBS-rTMS + Task-oriented Rehabilitation</title>
            <description>NBS-guided rTMS + task-oriented rehabilitation&#xD;
NBS-guided rTMS&#xD;
Task oriented rehabilitation</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS + Task-oriented Rehabilitation</title>
            <description>Sham rTMS + task-oriented rehabilitation&#xD;
Sham rTMS&#xD;
Task oriented rehabilitation</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Assessment: EuroQol EQ-5D Scale</title>
          <description>The EuroQoL EQ-5D is a visual analog scale scale from 0 (minimum) to 100 (maximum) assessing quality of life. Higher values indicate better quality of life.</description>
          <population>Intent to treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="15.7"/>
                    <measurement group_id="O2" value="6.9" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>To Assess Safety of Study Device Use, All Serious Adverse Events Will be Recorded and Compared Between Groups</title>
        <description>Serious Adverse Events were recorded and their occurrence was compared between treatment arms</description>
        <time_frame>Baseline - 6 months post-treatment</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>NBS-rTMS + Task-oriented Rehabilitation</title>
            <description>NBS-guided rTMS + task-oriented rehabilitation&#xD;
NBS-guided rTMS&#xD;
Task oriented rehabilitation</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS + Task-oriented Rehabilitation</title>
            <description>Sham rTMS + task-oriented rehabilitation&#xD;
Sham rTMS&#xD;
Task oriented rehabilitation</description>
          </group>
        </group_list>
        <measure>
          <title>To Assess Safety of Study Device Use, All Serious Adverse Events Will be Recorded and Compared Between Groups</title>
          <description>Serious Adverse Events were recorded and their occurrence was compared between treatment arms</description>
          <population>Intent to treat</population>
          <units>number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.63</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>NBS-rTMS + Task-oriented Rehabilitation</title>
          <description>NBS-guided rTMS + task-oriented rehabilitation&#xD;
NBS-guided rTMS&#xD;
Task oriented rehabilitation</description>
        </group>
        <group group_id="E2">
          <title>Sham rTMS + Task-oriented Rehabilitation</title>
          <description>Sham rTMS + task-oriented rehabilitation&#xD;
Sham rTMS&#xD;
Task oriented rehabilitation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <description>Not study device</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <description>Not study device involvement</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hip surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Increased lacrimation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spasms in hand</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hallucination olfactory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hallucination auditory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Medical Affairs</name_or_title>
      <organization>Nexstim Plc</organization>
      <email>jarmo.laine@nexstim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

